Related references
Note: Only part of the references are listed.Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas
Marina Salmon et al.
JOURNAL OF CLINICAL INVESTIGATION (2023)
Cell Type-specific Adaptive Signaling Responses to KRASG12C Inhibition
Hitendra S. Solanki et al.
CLINICAL CANCER RESEARCH (2021)
Diverse alterations associated with resistance to KRAS(G12C) inhibition
Yulei Zhao et al.
NATURE (2021)
Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis
Kosuke Tanaka et al.
CANCER CELL (2021)
The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin et al.
CANCER DISCOVERY (2020)
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Jenny Y. Xue et al.
NATURE (2020)
Targeting the MAPK Pathway in KRAS-Driven Tumors
Matthias Drosten et al.
CANCER CELL (2020)
Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer
Samarth Hegde et al.
CANCER CELL (2020)
The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas
Karmele Valencia et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
Vito Amodio et al.
CANCER DISCOVERY (2020)
Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics
Naiara Santana-Codina et al.
CELL REPORTS (2020)
Perspective Rational Cancer Treatment Combinations: An Urgent Clinical Need
Julia Boshuizen et al.
MOLECULAR CELL (2020)
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
Kirsten L. Bryant et al.
NATURE MEDICINE (2019)
Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
Conan G. Kinsey et al.
NATURE MEDICINE (2019)
Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy
Marie-Eve Beaulieu et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
KRASG12C inhibition produces a driver-limited state revealing collateral dependencies
Kevin Lou et al.
SCIENCE SIGNALING (2019)
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
Jordi Bertran-Alamillo et al.
NATURE COMMUNICATIONS (2019)
Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer
Mariano Ponz-Sarvise et al.
CLINICAL CANCER RESEARCH (2019)
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
Miriam Molina-Arcas et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
A view on drug resistance in cancer
Neil Vasan et al.
NATURE (2019)
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Sandra Misale et al.
CLINICAL CANCER RESEARCH (2019)
MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models
Zheng Xue et al.
CELL RESEARCH (2018)
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
Dietrich A. Ruess et al.
NATURE MEDICINE (2018)
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
Sara Mainardi et al.
NATURE MEDICINE (2018)
A novel three-dimensional high-throughput screening approach identifies inducers of a mutant KRAS selective lethal phenotype
Smitha Kota et al.
ONCOGENE (2018)
Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy
Paul W. Manley et al.
BIOCHEMISTRY (2018)
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2017)
FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions
Maria Larrosa-Garcia et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Cancer drug addiction is relayed by an ERK2-dependent phenotype switch
Xiangjun Kong et al.
NATURE (2017)
An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer
Adrian Vallejo et al.
NATURE COMMUNICATIONS (2017)
Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
Mark Merchant et al.
PLOS ONE (2017)
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Aravind Subramanian et al.
CELL (2017)
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression
Tikvah K. Hayes et al.
CANCER CELL (2016)
A combinatorial strategy for treating KRAS-mutant lung cancer
Eusebio Manchado et al.
NATURE (2016)
The Perseus computational platform for comprehensive analysis of (prote)omics data
Stefka Tyanova et al.
NATURE METHODS (2016)
The MaxQuant computational platform for mass spectrometry-based shotgun proteomics
Stefka Tyanova et al.
NATURE PROTOCOLS (2016)
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis
Jason Gotlib et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer
Hidenori Kitai et al.
CANCER DISCOVERY (2016)
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
Matthew P. Patricelli et al.
CANCER DISCOVERY (2016)
Enhanced MET Translation and Signaling Sustains K-Ras-Driven Proliferation under Anchorage-Independent Growth Conditions
Saori Fujita-Sato et al.
CANCER RESEARCH (2015)
Organoid Models of Human and Mouse Ductal Pancreatic Cancer
Sylvia F. Boj et al.
CELL (2015)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
Ryan B. Corcoran et al.
CANCER CELL (2013)
Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 Kinase in KRAS-Mutant Lung Cancer
Miriam Molina-Arcas et al.
CANCER DISCOVERY (2013)
Identification of Genes Upregulated in ALK-Positive and EGFR/KRAS/ALK-Negative Lung Adenocarcinomas
Hirokazu Okayama et al.
CANCER RESEARCH (2012)
Importin 7 and Exportin 1 Link c-Myc and p53 to Regulation of Ribosomal Biogenesis
Lior Golomb et al.
MOLECULAR CELL (2012)
Differential Pathogenesis of Lung Adenocarcinoma Subtypes Involving Sequence Mutations, Copy Number, Chromosomal Instability, and Methylation
Matthew D. Wilkerson et al.
PLOS ONE (2012)
Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data
Marina Sirota et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism
Ping Gao et al.
NATURE (2009)
An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors
D. Chitale et al.
ONCOGENE (2009)
Somatic mutations affect key pathways in lung adenocarcinoma
Li Ding et al.
NATURE (2008)
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman et al.
NATURE MEDICINE (2008)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability
SL Smith et al.
BRITISH JOURNAL OF CANCER (2005)
Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects
DA Tuveson et al.
CANCER CELL (2004)
Bioconductor: open software development for computational biology and bioinformatics
RC Gentleman et al.
GENOME BIOLOGY (2004)
Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context
C Guerra et al.
CANCER CELL (2003)
Survival analysis part I: Basic concepts and first analyses
TG Clark et al.
BRITISH JOURNAL OF CANCER (2003)
Summaries of affymetrix GeneChip probe level data
RA Irizarry et al.
NUCLEIC ACIDS RESEARCH (2003)
Gene-expression profiles predict survival of patients with lung adenocarcinoma
DG Beer et al.
NATURE MEDICINE (2002)
Share Paper
